Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies

Clinical Lymphoma and Myeloma

Volumn 7, Issue 2, 2006, Pages 106-108

  Shivakumar, Latha ^a   Ansell, Stephen ^b  

^a CIG Media Group   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Belimumab; Chronic lymphocytic leukemia; Hodgkin's lymphoma; Multiple myeloma; Non Hodgkin's lymphoma; Waldenstr m's macroglobulinemia

Indexed keywords

AMG 623; ANTINEOPLASTIC AGENT; APRIL PROTEIN; B CELL MATURATION ANTIGEN; BELIMUMAB; FLUORODEOXYGLUCOSE; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; LR 131; MONOCLONAL ANTIBODY; TRANSMEMBRANE ACTIVATOR AND CALCIUM MODULATING CYCLOPHILIN LIGAND INTERACTOR; TRANSMEMBRANE ACTIVATOR AND CALCIUM MODULATING CYCLOPHILIN LIGAND INTERACTOR IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LYMPHOCYTE DIFFERENTIATION; LYMPHOMA CELL; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; SHORT SURVEY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA;

EID: 33750191271     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.046     Document Type: Review

References (28)

1. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285:260-263.
2. Hahne M, Kataoka T, Shroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188:1185-1190.
3. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004; 104:2247-2253.
4. Dillon SR, Gross JA, Ansell SM, et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discos 2006; 5:235-246. Review.
5. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190:1697-1610.
6. Stein JV, Lopez-Fraga M, Elustondo FA, et al. APRIL modulates B and T cell immunity. J Clin Invest 2002; 109:1587-1598.
7. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293:2111-2114.
8. Varfolomeev E, Kischkel F, Martin F, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004; 24:997-1006.
9. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109:59-68.
10. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone b-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997; 90:766-775.
11. Zulman J, Jaffe R, Talal N. Evidence that the malignant lymphoma of Sjogren's syndrome is a monoclonal B-cell neoplasm. N Engl J Med 1978; 299:1215-1220.
12. Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192:1453-1466.
13. Planelles L, Carvalho-Pinto CE, Hardenberg G, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004; 6:399-408.
14. He B, Chadburn A, Jou E, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/ BLyS and APRIL. J Immunol 2004; 172:3368-3379.
15. Raje N, Kumar S, Hideshima T, et al. The role of B cell-activating factor (BAFF) in the biology of multiple myeloma (MM). Blood 2005; 106:944a (Abstract #3380).
16. Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2006. Epub ahead of print.
17. Elsawa SF, Novak AJ, Grote DM, et al. B-lymphocyte stimulator (BlyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 2006; 107:2882-2888.
18. Briones J, Timmerman JM, Hilbert DM, et al. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 2002; 30:135-141.
19. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005; 106:1012-1020.
20. Novak AJ, Bram RJ, Kay NE, et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100:2973-2979.
21. Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103:689-694.
22. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103:3148-3157.
23. Tai Y-T, Li X-F, Coffey R, et al. Role of BAFF in adhesion and growth of human multiple myeloma cells in the bone marrow environment. Proc Amer Assoc Cancer Res 2006; 47:1132 (Abstract #4823).
24. Oki Y, Georgakis GV, Migone T-S, et al. Serum BLyS level as a prognostic marker in patients with lymphoma. Blood 2005; 106:546a (Abstract #1926).
25. Rossi J-F, Borghini-Fuhrer I, Moreaux J, et al. A phase I/II study of TACI-Ig to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma or previously-treated Waldenstrom's macroglobulinemia. Blood 2005; 106:721a (Abstract #2566).
26. Belch A, McEwan A, Hewitt J, et al. Tumor targeting, dosimetry and clinical response data for lymphorad-131 (LR131; I-131 labeled B-lymphocyte stimulator) in patients with relapsed/refractory non-Hodgkin's lymphoma. Blood 2004; 104:214a (Abstract #750).
27. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetics, pharmacodynamics and toxicologic effects. Toxicol Sci 2006; 91:586-599.
28. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Immunity 2001; 15:289-302.